



CASE PC/4-32528A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV731066584US
Express Mail Label Number

March 30, 2006
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
CHEN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/06195

FILED: 12 JUNE 2003

U.S. APPLICATION NO: 10/517,874

35 USC §371 DATE: 13 DECEMBER 2004

FOR: CALCIUM SALTS OF INDOLE DERIVED STATINS

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is supplemental to the Information Disclosure Statement filed July 12, 2005. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/06195, copies are not required for consideration by the Examiner; however, Applicants want the references on the face of the patent, so the references are included in the PTO-1449 for initialing the references.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Mark Milstead
Attorney for Applicants
Reg. No. 45,825

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-4125

Date:



CASE PC/4-32528A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV731066584US
Express Mail Label Number

March 30, 2006
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CHEN ET AL.

APPLICATION NO: 10/517,874

FILED: DECEMBER 13, 2004

FOR: CALCIUM SALTS OF INDOLE DERIVED STATINS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,


Mark W. Milstead
Attorney for Applicants
Reg. No. 45,825

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-4125
Date: March 30, 2006

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
PC/4-32528A
APPLICATION NO.
10/517,874
APPLICANT
CHEN ET AL.
FILING DATE
DECEMBER 13, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AM	EP 0 547 000	6/16/03	Europe			<input type="checkbox"/>	<input type="checkbox"/>
AN	WO 02 36563A	5/10/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	
AS	
AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.